BIOINFOGATE’S OFF-X REACHES ONE MILLION SAFETY ALERTS
January 18, 2021
OFF-X has become the largest translational safety and toxicity intelligence portal for drugs and targets of pharmacological interest....
Continue reading
OFF-X has become the largest translational safety and toxicity intelligence portal for drugs and targets of pharmacological interest....
Continue readingBioinfogate will integrate JADER case reports and pharmacovigilance signals into OFF-X to complement its unique translational view of safety intelligence....
Continue readingThe Translatability Dashboard supports understanding of how toxicity events derived from experimental assays and animal models translate to the clinic...
Continue readingThe agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health. ...
Continue readingThe COVID-19 section features the latest safety alerts related to drugs being investigated as potential treatments, vaccinations or supportive care. ...
Continue readingLaunched in 2017, OFF-X has now reached 500,000 curated safety alerts corresponding to almost 15,000 targets of pharmacological interest and almost 14,500 drugs and biologics. ...
Continue readingBioinfogate is pleased to announce successful completion of the R&D innovation project "DEVELOPMENT OF AN ARTIFICIAL INTELLIGENCE PLATFORM TO ANTICIPATE AND MINIMIZE THE RISKS ASSOCIATED WITH THE SAFETY OF DRUGS FROM THEIR PHASE OF DISCOVERY THROUGH THEIR USE IN CLINICAL PRACTICE"....
Continue readingBioinfogate has been invited to a speak at the Chem-Bio Informatics Society (CBI) Annual Meeting ""Towards Seamless Integration of Structural Biology and Information Science"～Dawn of the AI era in drug discovery～" which takes place in Tokyo, Oct. 22-24, 2019. ...
Continue readingBioinfogate will be showcasing some of their recent developments at the Safety Pharmacology Society Annual Meeting in Barcelona, September 23-26, 2019....
Continue readingRISE selected OFF-X to support the work of researchers in drug R&D to perform target safety assessment for early projects. ...
Continue readingAnnounced today, the Vall d´Hebron Institute of Oncology - Bioinfogate collaboration will validate the utility of the OFF-X translational safety intelligence portal in the design of novel clinical trials, including first-in-human studies. ...
Continue readingBioinfogate will be showcasing some of their recent developments at booth 133....
Continue readingUnder this MTA, the FDA has agency-wide access to Bioinfogate’s translational safety intelligence portal, OFF-X. ...
Continue readingBioinfogate will cross-link the OFF-X translational safety intelligence portal with the Cortellis suite of solutions from Clarivate Analytics to enable enhanced insights for targets and drugs of interest....
Continue readingBioinfogate will be showcasing some of their recent developments....
Continue readingNecessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.